MX2018001315A - Inhibidores de fucosidasa. - Google Patents

Inhibidores de fucosidasa.

Info

Publication number
MX2018001315A
MX2018001315A MX2018001315A MX2018001315A MX2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A
Authority
MX
Mexico
Prior art keywords
inhibitors
tumors
fucosidase inhibitors
fucosidase
liver
Prior art date
Application number
MX2018001315A
Other languages
English (en)
Inventor
C Zankel Todd
Louise Isbell Sara
Anne Ko Amanda
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of MX2018001315A publication Critical patent/MX2018001315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms

Abstract

La presente invención se refiere, en general, a compuestos que son de utilidad como inhibidores de las enzimas fucosidasa y a métodos y composiciones para el tratamiento de tumores o cánceres, tales como trastornos hepáticos y tumores de hígado (por ejemplo, carcinoma hepatocelular), con un compuesto descrito en la presente.
MX2018001315A 2015-07-30 2016-07-29 Inhibidores de fucosidasa. MX2018001315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199194P 2015-07-30 2015-07-30
PCT/US2016/044607 WO2017019925A1 (en) 2015-07-30 2016-07-29 Fucosidase inhibitors

Publications (1)

Publication Number Publication Date
MX2018001315A true MX2018001315A (es) 2018-08-15

Family

ID=56616083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001315A MX2018001315A (es) 2015-07-30 2016-07-29 Inhibidores de fucosidasa.

Country Status (15)

Country Link
US (2) US9951013B2 (es)
EP (1) EP3328832B1 (es)
JP (2) JP6981961B2 (es)
KR (1) KR20180030699A (es)
CN (1) CN107848970B (es)
AR (1) AR105540A1 (es)
AU (2) AU2016298324A1 (es)
BR (1) BR112018000961A2 (es)
CA (1) CA2992033A1 (es)
IL (1) IL256662B (es)
MX (1) MX2018001315A (es)
RU (1) RU2765202C2 (es)
TW (1) TWI777923B (es)
WO (1) WO2017019925A1 (es)
ZA (1) ZA201800638B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PL2344129T3 (pl) 2008-10-07 2018-07-31 Horizon Orphan Llc Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych
PT2346509T (pt) 2008-10-07 2020-08-05 Horizon Orphan Llc Inalação de levofloxacina para redução da inflamação pulmonar
AU2010289326B2 (en) 2009-09-04 2015-09-24 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
AR105540A1 (es) 2015-07-30 2017-10-11 Raptor Pharmaceuticals Inc Inhibidores de fucosidasas

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US5153325A (en) 1989-06-27 1992-10-06 Monsanto Company Fucosidase inhibitor
US5017704A (en) 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5096909A (en) 1989-06-27 1992-03-17 Monsanto Company Fucosidase inhibitor
US5100797A (en) 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5240707A (en) 1990-04-12 1993-08-31 Merrell Dow Pharma Alpha-mannosidase and fucosidase inhibitors
WO1995020597A1 (en) * 1994-01-26 1995-08-03 Ciba-Geigy Ag Modified oligonucleotides
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
EP2323652A2 (en) * 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
JP6170675B2 (ja) * 2010-01-28 2017-07-26 ラプトール ファーマシューティカルズ インコーポレイテッド 受容体関連タンパク質（ｒａｐ）ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
ES2864774T3 (es) * 2011-12-22 2021-10-14 Centogene Ip Gmbh Combinación de un compuesto que tiene la capacidad de reorganizar una enzima lisosomal y Ambroxol y/o un derivado de Ambroxol
EP2890679A4 (en) * 2012-08-31 2016-05-04 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
AR105540A1 (es) 2015-07-30 2017-10-11 Raptor Pharmaceuticals Inc Inhibidores de fucosidasas

Also Published As

Publication number Publication date
RU2018107143A3 (es) 2019-12-27
TW201713620A (zh) 2017-04-16
AU2016298324A1 (en) 2018-01-25
WO2017019925A1 (en) 2017-02-02
CN107848970A (zh) 2018-03-27
IL256662A (en) 2018-02-28
RU2765202C2 (ru) 2022-01-26
BR112018000961A2 (pt) 2018-09-18
CA2992033A1 (en) 2017-02-02
KR20180030699A (ko) 2018-03-23
EP3328832A1 (en) 2018-06-06
ZA201800638B (en) 2022-08-31
RU2018107143A (ru) 2019-08-29
US10308607B2 (en) 2019-06-04
IL256662B (en) 2021-06-30
TWI777923B (zh) 2022-09-21
CN107848970B (zh) 2021-07-06
JP6981961B2 (ja) 2021-12-17
EP3328832B1 (en) 2021-03-03
US20190077756A1 (en) 2019-03-14
US20170029376A1 (en) 2017-02-02
JP2018522023A (ja) 2018-08-09
US9951013B2 (en) 2018-04-24
AR105540A1 (es) 2017-10-11
AU2020289858A1 (en) 2021-01-28
JP2021152078A (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2019011431A (es) Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1).
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
UA115983C2 (uk) Інгібітори днк-пк
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2019011496A (es) Composiciones de niraparib.
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
JO3155B1 (ar) معدِّل نكهة حلوة
MX2018001315A (es) Inhibidores de fucosidasa.
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2016010447A (es) Composiciones y metodos para tratar diabetes y enfermedades hepáticas.
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.